In a retrospective analysis of five patients with RR cHL who progressed on a phase II clinical trial for CS1001 (PD-L1 inhibitor), four demonstrated an excellent response when the treatment regimen transitioned to anti-PD1 therapy [90]. Here, CD274 is linked to classic Hodgkin lymphoma.